

**IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE**

APPLICANT : Judith PREUSCHEN et al.  
APPL. NUMBER : 10/574,426  
FILED : April 4, 2006  
FOR : DEVICE FOR DISPENSING VOLATILE COMPOUNDS IN  
A GEL TO THE AMBIENT AIR  
ART UNIT : 1751

---

October 20, 2006

VIA EFS (ELECTRONIC FILING SYSTEM)

**REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

A *Filing Receipt* (copy attached) for the above-captioned application has been received by Applicant's attorney. Upon review of this document errors were noted. The Patent Office is respectfully requested to make the following corrections and to issue a new and correct *Filing Receipt*:

On the *Filing Receipt*, the total number of claims is shown as 20. The correct total number of claims is 25.

In support of the above, a copy of the specification as filed with the patent application on April 4, 2006 is submitted herewith.

Please issue a *Corrected Filing Receipt* at your earliest convenience.

Respectfully submitted,  
NORRIS, McLAUGHLIN & MARCUS, P.A.



Andrew N. Parfomak  
Reg. No. 32,431

Norris, McLaughlin & Marcus P.A.  
875 Third Avenue, 18<sup>th</sup> Floor  
New York, New York 10022  
(212) 808-0700

PLEASE CHARGE ANY DEFICIENCIES  
UP TO \$300 OR CREDIT ANY EXCESS IN  
THE FEES DUE WITH THIS DOCUMENT  
TO OUR DEPOSIT ACCOUNT NO.  
14-1263.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/574,426	05/02/2006	1751	1840	10279255711334P1US <i>AWP</i>	25	20	2

CONFIRMATION NO. 7905

27389  
 NORRIS, MCLAUGHLIN & MARCUS  
 875 THIRD AVE  
 18TH FLOOR  
 NEW YORK, NY 10022

## FILING RECEIPT



\*OC000000020479552\*

Date Mailed: 09/19/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Judith Preuschen, Ludwigshafen, GERMANY;  
 Ralf Wiedemann, Ludwigshafen, GERMANY;

## Assignment For Published Patent Application

RECKITT BENCKISER N.V., HOOFFDDORP, NETHERLANDS

**Power of Attorney:** The patent practitioners associated with Customer Number 27389.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB04/04324 10/11/2004

## Foreign Applications

UNITED KINGDOM 0323659.3 10/09/2003

If Required, Foreign Filing License Granted: 09/18/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/574,426**

Projected Publication Date: 12/28/2006

Non-Publication Request: No

Early Publication Request: No

**Title**

Detergent body

**Preliminary Class**

510

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

5  
**DETERGENT BODY**

This application is filed as a 35 USC 371 application of PCT/GB2004/004324.

10 The present invention relates to a detergent body containing a high proportion of solid materials. The body is prepared by injection moulding.

15 In applications involving washing agents, detergents and other detergent formulation components, tablets have established a place for themselves on the market in recent years as a format that provides easy metering and is simple to use.

20 Tablets typically comprise a mixture of components that are solid at room temperature and components that are liquid at room temperature. Commonly the solid components are present in granular form for ease of processing and speed of dissolution and/or dispersion.

25 The tablets are normally prepared by admixture of the tablet components followed by compaction to a shaped body. These compressed tablets suffer from several disadvantages.

Firstly, even though the compaction pressure used is high the tablets are still friable. This leads to dust formation and, in some cases, tablet breakage. This problem has not been successfully addressed by the incorporation of binders within the tablet.

30 Additionally, as the tablet components are usually highly hygroscopic, on exposure to atmospheric air, the tablet absorbs moisture. With moisture absorption the tablet deforms and eventually loses its structural integrity. To counter this effect a water resistant container and/or wrapper is required to ensure tablet stability, requiring an additional step in the manufacturing process.

These and other disadvantages are also relevant for multi-phase tablets, tablets which contain one or more component formulations commonly present in a layered arrangement and/or body with insert formation.

5 Multi-phase tablets also suffer from complex manufacturing techniques: either a complex multi-stage manufacturing process involving a number of layers being compressed together (after possible separate pre-formation) and/or the insertion of an insert into cavity of a pre-formed body is required.

10 For the layered structures a compromise has to be reached between a sufficiently high compression pressure so that the layers are adequately bonded together and a sufficiently low compression pressure so that tablet in-wash dissolution and/or dispersion time is not unduly prolonged. This compromise often has unsatisfactory results leading to tablets having poor stability with detrimental effects such as layer separation.

15 For the tablets having an insert, there is the issue of insert addition which requires a highly precise manufacturing process and the problem of insert separation caused by poor adhesion to the tablet body.

20 Detergent tablets may also be prepared using extrusion techniques. In this method the tablet components are inserted into an intrusion device and extruded.

Tablets produced in this way also suffer from several disadvantages.

25 Most of the disadvantages arise as a result of the fundamentals of the extrusion process: the extrudate is typically tubular, which is then divided into tablet portions, usually in a cutting technique. It has been found to be very difficult to cut the extrudate into individual tablets without causing deformation to the tablet. Thus the tablets produced are not rectilinear but instead are distorted, especially around the cut edges.

30 Additionally due to the manner in which the extrudate is produced there is virtually no flexibility in the shape of the final tablet (with the exception of the shape of the extrusion die):

the extruded tablets must be based on a kind of tubular form. This problem is particularly exacerbated for multi-phase tablets.

Also for multi-phase tablets there is a further disadvantage in that little or no flexibility is allowed in the relative proportions in the phases. This problem is described more clearly in Patent Application WO-A-01/02532. Herein a multi-phased tablet (in this case two phases) is described, in which of the two phases the minor phase has to have a thickness of at least 5mm for the integrity of the tablet to be preserved.

It is an object of the present invention to mitigate and/or overcome the problems outlined above.

According to the first aspect of the invention there is provided a detergent body containing a high proportion of a solid component, wherein the detergent body is produced in an injection moulding process.

We have surprisingly found that high solid content compositions can be processed in an injection moulding process into a detergent body. This is unexpected as normally injection moulding is only considered suitable for composition predominantly comprised of thermoplastic materials that melt and/or soften (such as waxes) during the injection moulding process. Solid containing compositions are not normally processed in this way due to the detrimental abrasive effect of the solid component. This is particularly important in a detergent context as many detergent materials, such as builders, for example, are typically solid at room temperature.

Furthermore, the bodies have been found to have excellent physical properties including very smooth and/or glossy external surfaces and extremely low friability. Indeed friability has been found to be especially low at the apexes of the detergent body. Thus the problems exhibited by prior art tablet compositions of dust formation and/or high friability have been addressed.

Generally the detergent body formulation comprises a binder.

The binder is preferably present at 5-50 wt%, more preferably 5-40 wt% and most preferably 10-30 wt% (e.g. such as between 10-20 wt%) of the formulation of the detergent body.

5 The binder is most preferably a thermo-plastic material. Preferably the binder comprises a material which is solid at 30°C, most preferably at 35°C. Such material has been found to display excellent properties in body formation and body stability. More specifically the binder has been found to have the ability to aid the passage of the detergent body formulation into the injection moulding body and also to hold the body together after moulding.

10 Furthermore, the binder has been found to coat the solid component of the detergent body. This is advantageous as with the preferred binders, the previously observed problem of hygroscopicity of the solid components has been reduced. Also as the solid components are coated by the binder the problem of detrimental interaction of mutually incompatible solids (such  
15 as enzymes and bleaches) has been vastly reduced.

Preferred examples of binders include poly-ethylene-glycol (PEG) substituted and non-substituted synthetic and natural waxes (in both cases water soluble and non-water soluble, sugars and derivatives thereof, gelatine (combined with a sugar and/or a solvent (such as a liquid  
20 polyol, e.g. glycerine), non-ionic surfactants such as alkoxylated fatty acids and/or alcohols; water soluble or water dispersible oligomers and polymers (both substituted and non-substituted) such as poly-vinyl-alcohol (PVA), poly-vinyl-pyrrolidone (PVP), cellulose, polycarboxylic acids and co-polymers and/or derivatives thereof.

25 Most preferably the binder is PEG. Preferred examples of PEG have a molecular mass of 1500, 6000, 8000, 20000, 35000 or 8 million.

30 The term solid is to be understood as referring to a material which is solid at the processing temperature (temperature reached during the injection moulding process). Preferably the solid content of the detergent body is at least 50 wt%, more preferably at least 65 wt% and most preferably at least 80 wt%.



Generally the solid component comprises at least 50 wt% builders.

The preferred builder material is of the oligocarboxylate or polycarboxylate type, such as compounds selected from the group consisting of sodium citrate, sodium polyacrylate (and its co-polymers), sodium gluconate and mixtures thereof. Most preferably the builder is an alkali metal (e.g. sodium and/or potassium) citrate salt.

Optionally the builder material at least partially comprises a phosphorous based builder, such as a tripolyphosphate, e.g. sodium and/or potassium tripolyphosphate.

The solid component may comprise other conventional solid detergent components such as enzymes (e.g. proteases amylases or lipases), especially when in crystalline and/or particulate format, bleaches (such as percarbonate or perborate compounds, chlorine bleach compounds and peracid compounds), bleach activators (such as TAED or metal catalysts) and alkalis (such as hydroxides and/or carbonates).

Generally the detergent body formulation comprises a lubricant. Such a material has been found to display excellent properties in body formation. Namely the lubricant has the ability to facilitate the transport of the detergent body formulation into and/or within the injection moulding mould.

This has a positive effect on the energy required for the required detergent body processes. Also it has an effect on reducing the wear of the injection mould equipment.

The lubricant is preferably present at 0.1 wt% to 10 wt%, preferably from 0.2 wt% to 5 wt%. It has been found that at such a small percentage the effect of the lubricant on the final shape of the detergent body is minimised.

Preferred examples of lubricants include; fatty acids and derivatives thereof, such as alkali metal and ammonium salts of fatty acid carboxylates (e.g. ammonium stearate, sodium oleate, potassium laureate), also PEG and/or glycerol functionalised with fatty acid carboxylates

(e.g. PEG mono-oleate, PEG ricinoleate, glycerol mono-ricinoleate); sucrose glycerides; oils (olive oil, silicon oil, paraffin oil); and low melting point non-ionic surfactants.

5 The detergent body may have a coating. Where present the coating may be employed to provide an additional layer of protection to the detergent body. Additionally and/or alternatively the coating may be used to attach a second or further detergent body to the original detergent body.

Where present the coating comprises 0,1 wt% to 5 wt%, preferably from 0,2 wt% to 2 wt% of the detergent composition.

10 Most preferably the coating is dispersible and/or soluble in water. Preferred examples of coating materials include fatty acids, alcohols, diols, esters, ethers, mono and di-carboxylic acids, polyvinyl acetates, polyvinyl pyrrolidones, polylactic acids, polyethylene glycols and mixtures thereof.

15 Preferred mono-carboxylic acids comprise at least 4, more preferably at least 6, even more preferably at least 8 carbon atoms, most preferably between 8 and 13 carbon atoms. Preferred dicarboxylic acids include adipic acid, suberic acid, azelaic acid, subacic acid, undecanedioic acid, dodecandioic acid, tridecanedioic and mixtures thereof.

Preferred fatty acids are those having a carbon chain length of from  $C_{12}$  to  $C_{22}$ , most preferably from  $C_{18}$  to  $C_{22}$ .

20 The coating layer may also include a disrupting agent.

The detergent body may further include other common detergent components such as corrosion inhibitors, surfactants, fragrances, anti bacterial agents, preservatives, pigments and dyes.

25 The detergent body is preferably for use in an automatic washing process in an automatic washing machine. Most preferably the detergent body is for use in an automatic dishwashing process.

According to a second aspect of the invention there is provided a process for producing a detergent body containing a high proportion of a solid component, wherein the process comprises injection moulding.

5 It will be appreciated that features of the first aspect of the invention shall apply *mutatis mutantis* to the second aspect of the invention.

It has been found that detergent bodies produced using the production process of the second aspect of the invention have excellent properties resulting from the injection moulding component.

10 Firstly, it has been observed that the bodies produced have a high density. This is especially beneficial where the body is for use in an automatic washing machine (particularly a dishwashing machine) as normally there is only limited space for accommodating the detergent body. Thus by using the process of the present invention a small dense detergent body may be produced, wherein the said body contains sufficient detergent active to achieve its washing requirements yet is able to fit into the space provided in a washing machine.

15 Additionally as the body is produced by an injection moulding process there is much greater flexibility over the shape of the body produced. This can be useful if the body has to be accommodated in a specific space (see the paragraph above). It is also useful from a design freedom and/or aesthetic view point; no longer need the detergent body be based on the limited range of shapes that can be produced by compression or extrusion, any moulded shape can be  
20 produced.

Furthermore it has been observed that when bodies are produced by injection moulding, wherein the bodies comprise a particulate component, there is much greater flexibility of particle size of the particulate component. This is in contrast to particulate bodies produced in a  
25 compression process wherein to produce coherent bodies there is usually an upper limit on the particle size of around 1500  $\mu\text{m}$ : if the particle size is any greater the integrity of the body becomes compromised. Whereas in accordance with the process of the present invention bodies can be produced comprising a particulate component having a particle of bigger than 1500  $\mu\text{m}$ .

The use of larger particle sizes in the bodies provides several advantages in the production process. Primarily the use of larger particle sizes permits the use of a lower amount of binder with obvious cost saving advantages. Also the problem of pipework and/or conduit vessel coating, which is a recognised issue for small particles (especially when used in small quantities) is vastly reduced.

It has also been observed that a broad range of particle sizes can be used in the process according to the present invention. This is in contrast to conventional compression processes wherein there is a need for a narrow particle size distribution to avoid segregation of ingredients.

A preferred particle size is between 50µm and 2000 µm with any particle size distribution within these limits.

These advantages may be realised without incurring any detrimental effect on other tablet properties (such as strength, dissolution speed, etc)

The preferred processing method is as follows:

- a) Feed the materials to the barrel (hopper) of the injection unit (injection unit is to be understood as being the barrel, the screw and the nozzle) of the injection moulding machine.
- b) Cause the added admixture to be progressed along the barrel of the injection moulding machine towards the injection nozzle. As the admixture progresses along the barrel it is mixed and heated above the plastification temperature of the binder.
- c) The composition is injected into the mould at temperatures above the plastification temperature.
- d) In the mould the composition is allowed to chill.

e) The mould is opened and the shaped body is ejected from the mould.

The process may include one or more of additional steps(f) and / or (g): -

5 f) The body is coated with a coating material.

g) The body is packed (e.g. with foil wrapping, box or bag packing). The packaging material may be used to provide a moisture barrier.

10 In step (a) the component materials may be blended before addition to the barrel.

In step (a), as an alternative, one of the binder and / or lubricant components may be partially and/or fully added to the admixture inside the barrel of the injection unit of the machine by additional feeding stations.

15 In step (a) the component materials (particularly the binder) are added to the barrel preferably at a temperature below the plastification of the binder system to allow smooth feeding.

20 As an alternative in step (a) the component materials, optionally including the binder, may be heated above the plastification point of the binder and then added to the barrel.

In step (c) the pressure at the nozzle of the injection moulding machine while injecting is preferably higher than 50 bar, more preferably higher than 100 bar and most preferably higher  
25 than 200 bar.

In an alternative embodiment the process is performed using an injection unit which comprises a barrel equipped with a piston to press the detergent composition into the mould. In

this case the detergent composition needs to be heated above its plastification temperature and vigorously mixed before being placed in such injection unit. The detergent composition can then be injected into the mould.

5           The process of the present invention may be used in the preparation of multi-phase detergent bodies.

For manufacturing a multi phase detergent body the process is most preferably performed using a machine which comprises a plurality of injection units. Each injection unit is able to  
10 process a different composition.

Thus for manufacturing a multi phase detergent body the mould may be configured such that it can be accessed by a plurality of injection units. Thus a first injection unit may be used to inject a first composition into a first portion of the mould. Simultaneously (or subsequently) a  
15 second injection unit may be used to inject a second composition into a second portion of the mould. Movement of the mould relative to one or more of the injection units may occur at a part of the process.

As an alternative the mould may be opened after injection and chilling of the composition  
20 of the first phase of the detergent body. The original mould counter part which was moved in order to open the mould may be discarded and replaced with a second mould counter part. The mould may then be closed with the second mould counter part leaving a void space and the composition of the second phase injected therein.

25           As an further alternative the mould may be arranged such that it comprises a moveable member which affects the volume within the mould. Most preferably the member may be arranged in at least two orientations: in a first orientation a first volume is defined within the mould and in a second orientation a second (preferably larger) volume is defined within the

mould. Thus a first composition may be injected into the mould with the member in its first orientation. The first injected composition may then be allowed to cool. The member may then be moved to its second orientation, thus realising a void space into which a second composition may be injected.

5

A yet further alternative is that the mould may be opened after injection and chilling of the composition of the first phase of the detergent body. The first phase of the detergent body may be expelled from the mould and inserted into a second mould which after closing comprises a void space. The composition of the second phase may be injected into the void space.

10

For all options above the described process steps may be repeated for the injection of a third and/or subsequent composition. A combination of the different alternatives may also be used.

15 It has been observed in the process according to the invention that it can be used for the production of multi-phase detergent bodies having excellent properties. These properties include much greater flexibility in the relative arrangement of the phases as the arrangement of the phases in now no longer overruled by gravity and gravity controlled feed techniques as used in prior art multi-phased tablets produced by conventional compression processes.

20

Additionally the relative sizes of the phases is much more flexible: any relative size of phases is possible, no pre-set relationship is required as in extrusion processing prior art.

25 Furthermore, where a different binder is used in each phase, the release and/or dissolution and/or dispersion properties of each phase can easily be controlled. The said control has been found to be much more precise as it is no longer influenced by compression pressures; this has been found to be a particular problem wherein two phase tablets were formed by a compression method with the second phase being compressed on top of the already compressed first phase.

This led to variations in the compression pressures of the phases and variations in the tablet phase dissolution dispersion rate.

The invention is now described with reference to the following non-limiting examples.

5

### **Examples**

### **Formulation Preparation**

10

Several Formulations were prepared in accordance with the following table.

In each case tablets of 20g were produced. The tablets were rectangular in shape (26mm x 36mm x 14mm) with a small indentation on one of the largest faces (suitable for insertion of a  
15 second detergent composition component).



	Formulation							
	1	2	3	4	5	6	7	8
<b>Components %</b>								
STPP	24	24	24	24	24	32	32	37.6
Sodium-Citrate	48.25	48.25	48.25	48.25	53.25	17.6	17.6	-
Protease, speckles	0.75	0.75	0.75	0.75	0.75	-	-	0.6
Amylase, speckles	0.5	0.5	0.5	0.5	0.5	-	-	0.4
Sulphonated Polymer	5	5	5	5	5	-	-	-
Nonionic Surfactant	1.5	1.5	1.5	1.5	1.5	1.2	1.2	1.2
PEG M <sub>w</sub> = 20000 g/mol	20	20	15	15	10	-	-	-
Copolymer PVP-VA	-	-	5	5	5	-	-	-
Sodium Disilicate	-	-	-	-	-	2.8	2.8	2.8
Soda Ash	-	-	-	-	-	23.2	23.2	23.2
PA Homo-polymer	-	-	-	-	-	3.2	3.2	1.2
PEG M <sub>w</sub> = 6000 g/mol	-	-	-	-	-	20	-	20
Fatty Acid Alcohol 25 EO	-	-	-	-	-	-	20	-
Sodium Percarbonate	-	-	-	-	-	-	-	9.6
TAED	-	-	-	-	-	-	-	3.2
Sodium Phosphonate	-	-	-	-	-	-	-	0.04
Silver Corrosion inhibitor	-	-	-	-	-	-	-	0.2
<b>Granulation</b>	R	F	R	F	R	R	R	R
<b>Formulation Temperature (°C)</b>	100	100	100	100	100	70	70	70
<b>Formulation Pressure (bar)</b>	500	500	500	500	600	250	250	250

Definition of fine and rough granulation:

R = Rough Granulation: 200 to 1200 µm particle size (70% of granules are in the range of 400µm to 1000 µm).

F = Fine Granulation: 0-600 µm particle size (70% of granules are in the range of 50 µm to 300 µm)

### **Formulation Dissolution Measurement**

Each Formulation was tested to measure its dissolution time.

5

Two different dissolution tests were used as below.

#### **Test #1**

10 A Bauknecht Avanti GSF dishwasher is filled with 4L of water and heated up to 50°C.

The injection moulded Body is placed on the bottom of the dishwasher and allowed to dissolve. The spray arm is used to distribute the water as in a normal wash cycle.

15 The dissolution is measured by measuring conductivity of the water medium. When the conductivity value stays constant and does not increase any further it is assumed that the injection moulded Body has completely dissolved. This point is taken as the dissolution time. The measurement is repeated 3 times and the average value is calculated.

20 This test was carried out on Formulations 1 to 5 and the results are shown in Table 1.

**Table 1**

	Formulation				
	1	2	3	4	5
<b>Dissolution Time (min)</b>	22	23	42	40	50

## **Test #2**

A 1L beaker is filled with 800mL of tap water. The water is heated to 40°C and maintained at that temperature with a coil immersion heater having an associated contact thermometer.

With a standard pharmaceutical disintegration tester (Erweka brand) with up-and-down moving sieves the shaped bodies are moved up-and-down in the water. The point of complete dissolution is defined as the point when the whole shaped body is dissolved and/or disintegrated from the basket.

This test was carried out on Formulations 6 to 8 and the results are shown in Table 2.

**Table 2**

	Formulation		
	6	7	8
Dissolution Time (min)	20	45	21

## **Summary**

### **General:**

Powder Formulations with rough and fine granulation can be injection moulded into tablet shapes, (see particularly Formulation 1 and Formulation 2).

All shaped bodies had very smooth surfaces and a glossy appearance. The bodies all showed low dusting and very low friability.

The dissolution times of these Formulations (especially Formulations 1, 2 and 6) are very short and are similar to release profiles of current dishwasher tablets commercially available.

#### Granulometry:

Formulation 1 and Formulation 2 compare the use of different granule sizes in the process.

Surprisingly both granulometries can be used exchangeable yet produce tablets having very similar properties: the change in granulometry was shown to have no effect on the dissolution characteristics of the tablet products. Also there were no differences in the ease with which the tablets could be processed: the injection moulding process was unaffected by a change in particle granulometry. This is surprising and is in contrast to conventional compressed particulate tablets where the particle granulometry has a huge effect on tablet dissolution time.

#### Binder:

A binder content of 15 wt% is sufficient for a smooth injection moulding processing operation. The operation has been shown to be possible with a wide range of different binders.

We have shown that by modifying the binder system different dissolution speeds can be altered. This can be used to make multi phase products displaying sequential dissolution.

This effect may be illustrated with reference to Formulations 1 and 3. These Formulations have almost the same composition and are made in the same way. The difference

between the Formulations is that in Formulation 1 the binder is PEG ( $M_w=20000$  present at 20wt% of the Formulation) whereas in Formulation 3 the binder comprises 15wt% PEG  $M_w=20000$  and 5% polypyrrolidone-polyvinylacetate copolymer (PVP-VA). The dissolution times of Formulation 3 is twice that of Formulation 1.

5

A similar comparison can be made between Formulations 2 and 4 and also between Formulations 6 and 7.

Stability of ingredients:

10

Formulation 8 was stored at 30°C and 70%rH and was analytically checked after 6 weeks.

15 After 6 weeks it was found that Formulation 8 still had from 90 to 100 % of the starting material of TAED, BTA and percarbonate. This is more than typically obtained in storage tests of corresponding tablet products made by compression.

## CLAIMS

1. A detergent body containing a high proportion of a solid component, wherein the detergent body is produced in an injection moulding process.

5

2. A body according to claim 1, wherein the body comprises a binder.

3. A body according to claim 2, wherein the binder is present at 5-50 wt% of the detergent body.

10

4. A body according to claim 2, wherein the binder is present at , 5-40 wt% of the detergent body.

5. A body according to claim 3, wherein the binder comprises a thermoplastic material having a melting point of about 35°C.

15

6. A body according to claim 2 wherein the binder is PEG having a molecular mass of between 1500 to 35000.

7. A body according to claim 1, wherein the solid content of the detergent body is at least 50 wt%.

20

8. A body according to claim 7, wherein the solid content of the detergent body is at least , 65 wt%.

25

9. A body according to claim 7, wherein the solid content comprises at least 50 wt% builders.

10. A body according to claim 9, wherein the builder is an alkali metal citrate salt.

30

11. A body according to claim 1, wherein the detergent body formulation comprises a lubricant.

12. A body according to claim 11, wherein the lubricant is present at 0.1 to 10 wt%.
13. A detergent body according to claim 1 wherein the detergent body has a coating.
14. A process for cleaning articles in an automatic washing machine, which process  
5 comprises the step of providing a body according to claim 1 to the automatic washing machine.
15. A process for producing a detergent body having a high proportion of a solid component, wherein the process comprises injection moulding.
16. A process, according to claim 15 comprising the following steps:
- a) feeding the constituent materials to the barrel or hopper of an injection unit of an  
10 injection moulding machine;
  - b) causing the materials to be progressed along the barrel of the injection moulding machine towards an injection nozzle;
  - c) injecting the materials into a mould at a temperature above the plastification temperature of the binder;
  - 15 d) allowing the composition to chill in the mould; and,
  - e) opening the mould and ejecting the shaped body therefrom.
17. A process according to claim 16, wherein the body is coated with a coating material.
- 20 18. A process according to claim 16, wherein the body is packed with a packaging material.
19. A process according to claim 16, wherein the component materials are blended before addition to the barrel.
- 25 20. A process according to claim 16, wherein the binder or lubricant component(s) is at least partially added to the admixture inside the barrel of the injection unit of the machine by additional feeding stations.

21. A process according to claim 16, wherein in step (a) the component materials are added to the barrel at a temperature below the plastification of the binder system.
- 5 22. A process according to claim 16, wherein in step (a) the component materials are added to the barrel at a temperature above the plastification of the binder system.
23. A process according to claim 16, wherein in step (c) the pressure at the nozzle of the injection moulding machine while injecting is preferably higher than 50 bar.
- 10 24. A process according to claim 16, wherein the process is performed using a machine which comprises a plurality of injection units with each injection unit able to process a different composition.
- 15 25. A process for the preparation of multi-phase detergent bodies according to claim 16.



## ABSTRACT

A detergent body comprises a high proportion of a solid component. The detergent body  
5 is produced in an injection moulding process.